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Summary
 Background A standard linear-quadratic (LQ) model is now routinely used for clinical data 
analysis and the prediction of the clinical effect of radiotherapy. The typical a/b 
values suggested in the literature range from 10 to 20Gy for most tumours and 
early responding normal tissues, and from 2 to 5Gy for late responding tissues.
 Aim The estimation of a/b ratio values for planoepithelial lower lip cancer.
 Materials/Methods The clinical material is based on the records of 25 patients undergoing radical 
treatment with interstitial brachytherapy: 19 patients were administered brach-
ytherapy exclusively and 6 patients were treated postoperatively. The following 
stage arrangement was applied: T1 in 15 pts, T2 in 9 pts, N0 in 24 pts and N1 only 
in one T2 patient. Radiotherapy was based on HDR brachytherapy using the in-
terstitial technique. Patients with positive margins after surgery were qualiﬁ ed 
for postoperative brachytherapy. The dose was either speciﬁ ed at the reference 
80% isodose according to the Paris System or points calculated 3–5 mm from the 
macroscopic tumour. The average total dose was 38.3Gy, the number of fractions 
being 7 and the fraction dose 5.3Gy. The overall treatment time was 12 days. The 
average follow-up period was 30 months. A standard probit regression in con-
junction with a linear-quadratic model was used.
 Results The estimated value of the a/b ratio for lip cancer was 12Gy (±3.72*10–10 95% 
CI).
 Conclusions The estimated a/b ratio is consistent with a/b ratios published for squamous cell 
head and neck cancers.
 Key words lower lip cancer • LQ model • a/b ratio • brachytherapy
 Full-text PDF: http:/www.rpor.pl/pdf.php?MAN=10723
 Word count: 1553
 Tables: —
 Figures: 2
 References: 12
 Author’s address: Andrzej Lebioda Centre of Oncology, Romanowskiej 2 Str., 85-796 Bydgoszcz, Poland,
  e-mail: lebiodaa@co.bydgoszcz.pl
Received: 2006.12.07
Accepted: 2007.02.12
Published: 2007.08.31
Authors’ Contribution:
 A Study Design
 B Data Collection
 C Statistical Analysis
 D Data Interpretation
 E Manuscript Preparation
 F Literature Search
 G Funds Collection
Original Paper
207
Rep Pract Oncol Radiother, 2007; 12(4): 207-210
BACKGROUND
A standard linear-quadratic (LQ) model is now 
routinely used for clinical data analysis and the 
prediction of the clinical effect of radiotherapy. 
Typical a/b values suggested in the literature 
range from 10 to 20Gy for most tumours and ear-
ly responding normal tissues, and from 2 to 5Gy 
for late responding tissues [1–4].
Radical radiotherapy of lip cancer has a long tra-
dition at our centre. Most of our patients, except 
those with T3, T4 stage and N>0, were originally 
qualiﬁ ed for external beam irradiation. In the 
late 1990s we experienced limited access to ex-
ternal beam irradiation machines as a result of 
the exchange of the radiotherapy line at our cen-
tre, which led to a new group of patients qualiﬁ ed 
for interstitial brachytherapy schedules. Due to 
the lack of standards we had to apply a treatment 
schedule of a 6Gy fraction given once a week. In 
the presence of good implant tolerance and an 
acute reaction, we reduced the fraction dose to 
3Gy and planned 17 fractions given once or twice 
per day for 14 days to give a 51Gy total dose. The 
wide range of fractions and total doses resulting 
from the new treatment schedule was the reason 
why we started to carry out the present analysis.
The discussion of a/b ratio values as they relate to 
prostate cancer [5–7] and the conclusions based 
on low a/b ratio values as well as the consequenc-
es of the beneﬁ t of high fraction doses were ad-
ditional factors determining our work. Our dis-
cussion uses the same argument as Brenner and 
Martinez [8], ﬁ rstly involving of high fraction dos-
es using the interstitial technique far beyond the 
external beam radiotherapy range, and, as a con-
sequence, pushing the high biological effective-
ness of such fractionation schedules. Secondly 
we omitted the fact that the dose distribution in 
HDR brachytherapy interstitial technique was 
non-homogeneous.
AIM
The estimation of a/b ratio values for planoep-
ithelial lower lip cancer.
MATERIALS AND METHODS
Our clinical material is based on the records of 25 
patients treated radically with interstitial brachy-
therapy at the Centre of Oncology in Bydgoszcz 
and the Cancer Centre – Institute of Oncology in 
Gliwice between May 1999 and December 2004. 
Nineteen patients were solely administered brach-
ytherapy and 6 patients were treated post-opera-
tively. All patients had pathologically conﬁ rmed 
squamous cell carcinoma of the lower lip. The fol-
lowing stage arrangement was applied: T1 in 15 
pts, T2 in 9 pts, N0 in 24 pts and N1 only in one T2 
patient out of the 25. Patients with inﬁ ltration of 
the mouth corner were excluded from this study. 
One patient also had simultaneous lung cancer, 
two patients had previous cancer of the larynx 
and one patient had suffered a cerebral stroke. 
According to our recommendations post-opera-
tive brachytherapy was indicated in the cases of 
microscopic non-radical treatment or lack of in-
formation about the features of the margin.
Radiotherapy was based on 192Ir HDR brachy-
therapy using the interstitial needle technique. 
Patients with positive or unknown margins af-
ter surgery (6 pts.) were eligible for post-oper-
ative brachytherapy. The dose was speciﬁ ed ei-
ther at the reference 80% isodose according to 
the Paris System or points calculated 3–5 mm 
from the macroscopic tumour or tumour bed. 
The average total dose was 38.3Gy (range: 15 
to 50Gy), the average number of fractions be-
ing 7 (range: 1 to 15), and the average fraction 
dose 5.3Gy (range: 3 to 15Gy). The average V100 
was 4.8ccm, (range: 0.7–17ccm) and V200 1.6ccm 
(range: 0.2–6.7ccm). The mean treatment time 
per fraction was less than 3 min, depending on 
the dose and source activity. The mean number 
of interstitial needles was 2 (range: 1 to 5). The 
overall treatment time (OTT) for brachytherapy 
alone was 12 days (range: 1 to 40). The mean fol-
low-up period was 30 months (range: 24 to 43). 
Local control, deﬁ ned as no evidence of the dis-
ease at the 24th month, constituted the clinical 
endpoint of our study.
All patients (25) showed a complete response 
and none of them experienced local recurrence. 
In all patients treated with brachytherapy as the 
sole method, epitheliolysis and oedema around 
the implant appeared. We did not observe late 
effects, i.e. ﬁ brosis, skin retraction, hypo- or hy-
perpigmentation or ulceration. The only cosmet-
ic defect was a little tissue loss at the place of the 
primary inﬁ ltration, and teleangiectiasis in two 
patients. No complications involving the implant 
(bleeding, infection) were noted.
Statistical analysis covered standard logistic regres-
sion in conjunction with a linear-quadratic model 
(LQ). The application of a logit regression mod-
el is based on the estimations of linear regression 
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parameters (independent variable) which inﬂ u-
ence local control probability (dependent var-
iable) on the assumption that the variable has 
a normal distribution. The general form of the 
model may be described by the equation: 
p = exp(a0 + a1*x1 + a2*x2 +…+ an*xn)/
(1+ exp(a0 + a1*x1 + a2*x2 +…+ an*xn))
Where
p is the local control probability,
xi is the independent variable i and
ai is the parameter of item independent variable.
In one particular case, using the LQ model, the 
above equation assumes the form: 
p = exp (a0 + a*TD + b*TD*df)/
(1+ exp (a0 + a*TD + b*TD*df))
Where
a, b are the LQ equation parameters,
TD is the total dose,
df is the fraction dose and
TD*df is the product of the total dose and frac-
tion dose.
Clinical data were presented in 3 columns, com-
prising total dose, total dose and fraction dose 
product, and clinical effect assessment. In our 
work tumour control at the 24th month was scored 
as “1” and lack of local control as “0”. Using the 
maximal likelihood method the estimated coef-
ﬁ cients were ﬁ tted. Additionally, standard errors 
were estimated. In order to obtain local control 
in 100% of patients the following parameters had 
to be introduced in the analysis: the total dose of 
0Gy, the fraction dose of 0Gy, with no local control 
(“0” score). The conﬁ dence interval (CI) of the 
a/b ratio was calculated as the sum of the relative 
conﬁ dence interval of the a and b parameters and 
a/b value product. Cases weighting equal to the 
value of fraction dose was excepted. All the calcu-
lations were made using the maximum-likelihood 
procedures of the Statistica ’99 software [9].
RESULTS
The estimated a/b ratio was 12Gy (±3.72*10–10 
95% CI). The estimated a parameter was 0.587Gy–1 
(±9*10–11Gy–1, 95% CI) and the b parameter was 
0.05Gy–2 (±7*10–12Gy–2, 95% CI). Figure 1 is a sur-
face plot of the local control probability as a func-
tion of the total dose (TD) and the product of the 
total dose and the fraction dose (TDxdf).
DISCUSSION
By applying a linear-quadratic model in clinical 
practice we were able to estimate equivalent doses 
safely. The basic element of the LQ model is the 
a/b parameter. However, estimation of the basic 
and also the critical LQ model parameter which 
is the a/b ratio involves a wide, or even very wide, 
95 percent conﬁ dence interval. The estimated a/
b ratio of 12Gy is consistent with what is expected 
for the tumours investigated. Gordon Steel [10] 
presents six a/b ratios for head and neck can-
cers. The 95% conﬁ dence limit for two cancers 
(vocal cord and orpharyx) is not estimated; for 
the next two cancers (buccal mucosa and tonsil) 
it is between 3.6Gy and inﬁ nity; for larynx carci-
noma it is 10–20Gy; and for nasopharynx cancer 
it is from 11 to 43Gy. Such a wide conﬁ dence in-
terval depends on at least two factors. The ﬁ rst 
one is the method of analysis. The superiority of 
a nonlinear regression (logit or probit) over a re-
ciprocal dose technique (Figure 2) is unquestion-
able [11]. We employed the former technique in 
our work using a method proposed by Howard 
Thames [12]. The logit transformation enables 
one to connect the biological effect, expressed as 
a percentage of local controls or complications, 
with fractionation parameters (TD, TD*df), pre-
serving the simplicity of the LQ model.
The other factor is the clinical data set based 
on schemes characterized by little variability of 
Figure 1. A surface plot of the local control probability as a 
function of the total dose and the product of the total dose and 
fraction dose.
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fractions and, in consequence, by the total dose. 
In our material, the ratio between the lowest and 
the highest fraction dose was 5× (3–15Gy) and 3× 
(15–50Gy) as regards the total dose. This was the 
result of the lack of HDR brachytherapy stand-
ards in the treatment of lower lip cancer. At the 
beginning we chose a treatment schedule of 6Gy 
per fraction given once a week. In the presence of 
good implant tolerance and acute reaction we re-
duced the fraction dose to 3 Gy and planned 17 
fractions given once or twice daily over 14 days, 
expecting a lowering of late effect risks. A wide 
range of fractions and total doses due to the var-
iability of treatment schedules enabled us to car-
ry out this analysis.
A correction for repopulation was not introduced 
because of the short OTT and for incomplete re-
pair due to the interval between those fractions 
being longer than 6 hours.
The disadvantage of our analysis is that the 
number of patients is small. The most important 
source of error may lie in the incorrect estima-
tion of dose distributions or their speciﬁ cations 
when using non-homogeneous dose distribution 
in contrast to external beam radiotherapy employ-
ing a homogeneous dose distribution.
CONCLUSIONS
We estimated the a/b ratio value to be 12Gy 
(±3.72*10–10 95% CI), which is consistent with 
the previous estimation for squamous cell head 
and neck tumours.
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Figure 2. A linear plot of the local control probability as a function of the reciprocal total dose and the fraction dose, α/β value 6Gy, 
95%CI 1–30Gy.
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